There are multiple biosimilars in development for a range of therapy areas from cancer and diabetes to ophthalmology and respiratory. High-value mAbs such as Roches Avastin (bevacizumab), Abbvies Humira (adalimumab) and Janssen/Merck & Cos Remicade (infliximab) are being targeted by multiple biosimilar developers. But which companies are leading the market? What products are being targeted? Where is development geographically concentrated? What licensing and collaboration opportunities are there?

The answers to these and many other questions can be found in Charting the Global Biosimilars Pipeline. This comprehensive report provides the most detailed evaluation of the biosimilar development landscape worldwide. Rich in tables, charts and statistics, it delivers the critical data you need to understand trends, identify opportunities and assess competitive threats.

Why this report is important

What is the true potential of the much hyped biosimilar market? At present there are 260 biosimilar products which are approved in at least one market – and many of those are first generation products such as hormones. The future, however, is looking more interesting with 188 biosimilars in development, 61 of which are in Phase III trials. The number of high value mAbs for a wide range of conditions has increased. Development continues to be concentrated in countries such as India, China, Bangladesh, Iran and South Korea. In contrast, high development cost, originator defence strategies and more stringent regulatory regimes are pegging back development interest in the US and Europe. In the US there are 6 companies with 8 biosimilars registered . The sector is dominated by originator companies such as Pfizer, Amgen and Merck & Co. Europe is scarcely better with 9 companies and 13 biosimilars registered. The global biosimilar market is maturing both in its scope and ambitions.

Use this report to:

Profile the most active biosimilar companies and their pipelines
Know the development status of biosimilars targeting high-value brands and the companies that are involved
Identify licensing and collaboration opportunities
Assess the clinical trials that are underpinning biosimilar development
Review 61 biosimilar projects in Phase III and anticipate where they will make a market impact
Establish where biosimilar development around the world is concentrated and evaluate the companies driving progress

Report contents at a glance:

Overview
Biosimilars by therapy area
Biosimilars by product class
Most popular/bestselling biosimilar product candidates
Biosimilars by development stage
Leading biosimilar companies
Biosimilar pipeline by product

Biosimilar Pipeline By Product:
Each biosimilar monograph utilises well-structured tables and charts to provide clear view of…
Details provided, where availableClass
Mode of action
Key therapeutic area(s)
Route of administration
Reference product
Originator
RP sales
RP indications
US/EU patent information

Products analysed :
Abatacept
Abciximab
Adalimumab
Aflibercept
Anakinra
Bevacizumab
Certolizumab Pegol
Cetuximab
Daclizumab
Darbepoetin Alfa
Denosumab
Eculizumab
Enoxaparin
Epoetin Alfa
Etanercept
Filgrastim
Follitropin Alfa
Infliximab and so on.....

Biosimilar Products By Company:

Each company monograph utilises well-structured tables and charts to provide, where relevant and available, a clear view of…

Details provided, where available
Class
Mode of action
Key therapeutic area(s)
Route of administration
Reference product
Originator
RP sales
RP indications
US/EU Patent information
Number of companies developing this biosimilar
Biosimilar development status
Biosimilar brand/lab code
Biosimilar developer(s)
Location of biosimilar developer(s) and so on.....

Category: Healthcare Market
Contact Details:
Aarkstore Enterprise
+91 9987295242 | [email protected] | aarkstore.com